Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given an average rating of “Moderate Buy” by the eighteen research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $42.12.

Several research analysts have recently commented on the company. Chardan Capital lowered their price target on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating for the company in a research report on Friday. Morgan Stanley lowered Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. Barclays lowered their price target on Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research report on Friday, November 8th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $90.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, November 19th.

Intellia Therapeutics Stock Down 7.1 %

NTLA stock opened at $10.09 on Monday. The business has a fifty day moving average of $10.90 and a two-hundred day moving average of $15.72. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -1.85 and a beta of 1.80. Intellia Therapeutics has a 52-week low of $8.96 and a 52-week high of $34.87.

Insider Buying and Selling at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. The trade was a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 29,000 shares of company stock valued at $352,551. 3.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Several institutional investors have recently modified their holdings of NTLA. Blue Trust Inc. boosted its stake in shares of Intellia Therapeutics by 182.7% during the 3rd quarter. Blue Trust Inc. now owns 4,189 shares of the company’s stock worth $94,000 after acquiring an additional 2,707 shares in the last quarter. Eastern Bank purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter worth approximately $41,000. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Intellia Therapeutics by 34.7% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 53,721 shares of the company’s stock worth $1,104,000 after acquiring an additional 13,839 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Intellia Therapeutics by 27.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after acquiring an additional 794 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Intellia Therapeutics by 72.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,537 shares of the company’s stock worth $401,000 after acquiring an additional 8,204 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.